DTx Pharma
AcquiredSan Diego, US · Founded 2017 · Delaware corporation · 3 known investors
Biotech
Founders & leadership
DTx Pharma was founded in 2017 by Arthur T Suckow and Arthur Suckow, Ph.D..
AT
Arthur T SuckowCo-founder
AS
Investors · 3
Reported raises · per SEC filings
Form D private placements$113.4M disclosed across 4 rounds · 2017–2021
▶$100.2MraisedMar 2021 · 22 investors · PharmaceuticalsRule 506(b)
▶$100.2MraisedMar 2021 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur SuckowExecutive Officer, Director
- John RundyDirector
- Jeffrey FriedmanExecutive Officer, Director
- Niki UpperExecutive Officer
- Matthew HammondDirector
- Daniel BeckerDirector
- Tim ScottDirector
- Andrew AdamsDirector
- Offering amount
- $100.2M
- Amount sold
- $100.2M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$200KraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey FriedmanExecutive Officer, Director
- John GrundyDirector
- Arthur SuckowExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $200K
- Minimum investment
- $50K
- Placement agents
- na
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$12MraisedSep 2019 · 60 investors · PharmaceuticalsRule 506(b)
▶$12MraisedSep 2019 · 60 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur T SuckowExecutive Officer, Director
- John GrundyDirector
- Jeffrey FriedmanDirector
- Offering amount
- $12.5M
- Amount sold
- $12M
- Minimum investment
- $10K
- Placement agents
- na
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1MraisedJun 2018 · 15 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJun 2018 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur T SuckowExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1M
- Minimum investment
- $1
- Placement agents
- na
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $387.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $313K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $321.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $301.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who founded DTx Pharma?
- DTx Pharma was founded by Arthur T Suckow, Arthur Suckow, Ph.D. in 2017.
- Who are DTx Pharma's investors?
- DTx Pharma's investors include Access Biotechnology, ExSight Ventures, RA Capital.
- How much funding has DTx Pharma raised?
- DTx Pharma has disclosed $113.4M raised across 4 rounds.
- Where is DTx Pharma headquartered?
- DTx Pharma is headquartered in San Diego, US.